title: Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.
abstract: The primary goal of this phase II study was to determine the efficacy of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus 5-fluorouracil in patients with pancreatic cancer. Eligibility criteria included nonresectable locally advanced or metastatic pancreatic adenocarcinoma and measurable disease. Gemcitabine at 1,000 mg/m(2) and leucovorin at 20 mg/m(2) were administered intravenously 30 minutes before 5-fluorouracil 600 mg/m(2), weekly for 3 of every 4 weeks. Twenty nine patients were enrolled. The overall response rate was 21% (95% confidence interval: 8% to 40%), consisting of one complete response and five partial responses; 16 patients (55%) had stable disease. Median survival was 8.4 months (95% confidence interval: 2.6 to 14.2), and actuarial 1-year survival was 36%. Neutropenia (grade 3 only) was reported in 3.4% of patients, but was generally of short duration. No thrombocytopenia or evidence of cumulative myelosuppression was observed. The only significant nonhematologic events were grade 3 diarrhea and alopecia (both 3.4%). Gemcitabine plus 5-fluorouracil is active and well tolerated compared with results reported for each of these single agents. Thus, this combination justifies future comparative clinical trials. Semin Oncol 28 (suppl 10):44-49.
authors.affiliation: Grupo de Tumores Gastrointestinales, Hospital Fernandez, Servicio de Oncología, Cerviño 3356 CP 1425, Buenos Aires, Argentina.
authors.forename: A
authors.initials: A
authors.lastname: Marantz
authors.forename: S
authors.initials: S
authors.lastname: Jovtis
authors.forename: E
authors.initials: E
authors.lastname: Almira
authors.forename: L
authors.initials: L
authors.lastname: Balbiani
authors.forename: J L
authors.initials: JL
authors.lastname: Castilla
authors.forename: L
authors.initials: L
authors.lastname: Fein
authors.forename: D
authors.initials: D
authors.lastname: Lewi
authors.forename: G
authors.initials: G
authors.lastname: Pasccon
authors.forename: R
authors.initials: R
authors.lastname: Pinckevicius
authors.forename: G
authors.initials: G
authors.lastname: Uranga
authors.forename: M
authors.initials: M
authors.lastname: Abal
authors.forename: M
authors.initials: M
authors.lastname: Muiño
authors.forename: M
authors.initials: M
authors.lastname: Reale
authors.forename: S
authors.initials: S
authors.lastname: Agusto
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002955:Leucovorin; D005472:Fluorouracil; D000093542:Gemcitabine